(Q40944828)

English

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group

scientific article published on January 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group (English)

1 reference

Europe PubMed Central

25 September 2017

1 reference

based on heuristic

inferred from title

author name string

Schellhammer P

1

1 reference

Europe PubMed Central

25 September 2017

Sharifi R

2

1 reference

Europe PubMed Central

25 September 2017

Block N

3

1 reference

Europe PubMed Central

25 September 2017

Soloway M

4

1 reference

Europe PubMed Central

25 September 2017

Venner P

5

1 reference

Europe PubMed Central

25 September 2017

Patterson AL

6

1 reference

Europe PubMed Central

25 September 2017

Sarosdy M

7

1 reference

Europe PubMed Central

25 September 2017

Vogelzang N

8

1 reference

Europe PubMed Central

25 September 2017

Jones J

9

1 reference

Europe PubMed Central

25 September 2017

Kolvenbag G

10

1 reference

Europe PubMed Central

25 September 2017

language of work or name

0 references

publication date

1 January 1996

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

47

1 reference

Europe PubMed Central

25 September 2017

1A Suppl

1 reference

Europe PubMed Central

25 September 2017

54-60; discussion 80-4

1 reference

Europe PubMed Central

25 September 2017

Current clinical studies with a new nonsteroidal antiandrogen, Casodex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Leuprolide with and without flutamide in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide as primary treatment for metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980010-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(96)80010-0

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40944828&oldid=1911072519"